Abstract
None of the studies conducted on people who have reduced the number of antivirals taken in their regimen have shown good results. Research has consistently shown that these people have an increased viral load count when one or more drugs are discontinued. Results from a French study show some promise in switching from a protease inhibitor to a nonnucleoside analogue reverse transcriptase inhibitor (NNRTI) such as Viramune (Nevirapine) or Sustiva (efavirenz). Fifteen out of sixteen participants maintained viral load levels below 200 copies when they changed to an NNRTI regimen. The one person whose viral load increased had taken an NNRTI drug before, although its use was prohibited in eligibility requirements. The strategy may work for people at varying stages of the disease, but larger studies are needed to confirm the results. Also, a fifth protease inhibitor, Amprenavir (Agenerase) has received FDA approval. Trial results are summarized, and side effects and drug interactions with Amprenavir are described.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
